Achieving High-Titer Bispecific Antibody Production with >98% Heterodimer Purity
Bispecific antibodies (bsAbs) represent a significant advancement in biologic therapeutics. However, their development poses key challenges, such as the need for extensive pairing screening to identify the optimal ones and addressing low yield and purity during production. Each bsAb format also presents unique complexities in the production process.
This white paper introduces innovative strategies to tackle these challenges, from high-throughput, small-scale production for optimal pairing identification, to overcoming unique challenges across diverse formats like CrossMab, ScFv-Fab, and more. By leveraging innovative approaches, we achieve high-titer CHO production of bsAbs with >98% heterodimer purity and endotoxin level <0.1 EU/mg.
Download this white paper to discover:
1. Innovative production platforms enabling rapid and cost-effective identification of optimal bsAb pairings.
2. Tailored solutions for different bsAb formats, leveraging LC-MS assisted purification to achieve >98% heterodimer purity.
3. HC/LC chain ratio optimization to improve both titer and purity.
You're almost there!
Fill out the form below to get permanent access to this free White Paper.
WuXi Biologics is a leading global CRDMO, with the R represented by our premium-quality CRO Services. With expertise in diverse drug modalities, we deliver comprehensive research services, including antibody discovery, protein production and engineering, and in vitro/in vivo testing, to seamlessly advance our clients' molecules from concept to CMC development.
